Cardiovascular protection by SGLT2 inhibitors: an integrative review of mechanistic networks, clinical evidence, and safety considerations
Sodium-glucose cotransporter 2 (SGLT2) inhibitors were originally developed as glucose-lowering agents for type 2 diabetes mellitus, but accumulating evidence has demonstrated their broad cardiovascular and cardiorenal benefits beyond glycemic control. In particular, empagliflozin and dapagliflozin...
Enregistré dans:
| Auteurs principaux: | , , , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Frontiers Media S.A.
2026-06-01
|
| Collection: | Frontiers in Cardiovascular Medicine |
| Sujets: | |
| Accès en ligne: | https://www.frontiersin.org/articles/10.3389/fcvm.2026.1776906/full |
| Tags: |
Pas de tags, Soyez le premier à ajouter un tag!
|